Literature DB >> 20176499

Guanidino compound levels in blood, cerebrospinal fluid, and post-mortem brain material of patients with argininemia.

Joshua L Deignan1, Peter P De Deyn, Stephen D Cederbaum, Arno Fuchshuber, Bernhard Roth, Wieland Gsell, Bart Marescau.   

Abstract

The paucity of hyperammonemic crises together with spasticity, only seen in human arginase I deficient patients and not in patients with other urea cycle disorders, forces a search for candidates other than ammonia to associate with the pathophysiology and symptomatology. Therefore, we determined arginine together with some catabolites of arginine in blood and cerebrospinal fluid of these patients as well as in extremely rare post-mortem brain material of two patients with argininemia. The levels of alpha-keto-delta-guanidinovaleric acid, argininic acid and alpha-N-acetylarginine correlate with the arginine levels in blood and cerebrospinal fluid of patients with imposed or spontaneous protein restriction. The levels in blood are higher than the upper limit of normal in all studied patients. In addition to the highly increased levels of these same compounds in blood of a child with argininemia, the increase of guanidinoacetic acid, 24h before death, is remarkable. However, the manifest increases of these studied catabolites of arginine are not seen in post-mortem brain material of the same pediatric patient. Otherwise a clear increase of guanidinoacetic acid in post-mortem brain material of an adult patient was shown. A similar, comparable increase of homoarginine in both studied post-mortem brain materials is observed. Therefore the study of the pathobiochemistry of arginine in argininemia must be completed in the future by the determination of the end catabolites of the nitric oxide and agmatine biosynthesis pathways in the knockouts as well as in the patients to evaluate their role, together with the here studied catabolites, as candidates for association with pathophysiology and symptomatology. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20176499     DOI: 10.1016/j.ymgme.2010.01.012

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  17 in total

1.  Creatine metabolism in urea cycle defects.

Authors:  Sara Boenzi; Anna Pastore; Diego Martinelli; Bianca Maria Goffredo; Arianna Boiani; Cristiano Rizzo; Carlo Dionisi-Vici
Journal:  J Inherit Metab Dis       Date:  2012-05-30       Impact factor: 4.982

2.  Alterations in neuronal metabolism contribute to the pathogenesis of prion disease.

Authors:  Julie-Myrtille Bourgognon; Jereme G Spiers; Hannah Scheiblich; Alexey Antonov; Sophie J Bradley; Andrew B Tobin; Joern R Steinert
Journal:  Cell Death Differ       Date:  2018-06-18       Impact factor: 15.828

Review 3.  Arginase-1 deficiency.

Authors:  Yuan Yan Sin; Garrett Baron; Andreas Schulze; Colin D Funk
Journal:  J Mol Med (Berl)       Date:  2015-10-14       Impact factor: 4.599

4.  Hepatic arginase deficiency fosters dysmyelination during postnatal CNS development.

Authors:  Xiao-Bo Liu; Jillian R Haney; Gloria Cantero; Jenna R Lambert; Marcos Otero-Garcia; Brian Truong; Andrea Gropman; Inma Cobos; Stephen D Cederbaum; Gerald S Lipshutz
Journal:  JCI Insight       Date:  2019-09-05

5.  Arginase I deficiency: severe infantile presentation with hyperammonemia: more common than reported?

Authors:  Shailly Jain-Ghai; Sandesh C Sreenath Nagamani; Susan Blaser; Komudi Siriwardena; Annette Feigenbaum
Journal:  Mol Genet Metab       Date:  2011-07-13       Impact factor: 4.797

6.  Rescue of the Functional Alterations of Motor Cortical Circuits in Arginase Deficiency by Neonatal Gene Therapy.

Authors:  Gloria Cantero; Xiao-Bo Liu; Ronald F Mervis; Maria T Lazaro; Stephen D Cederbaum; Peyman Golshani; Gerald S Lipshutz
Journal:  J Neurosci       Date:  2016-06-22       Impact factor: 6.167

7.  Clinical phenotype, biochemical profile, and treatment in 19 patients with arginase 1 deficiency.

Authors:  Martina Huemer; Daniel R Carvalho; Jaime M Brum; Özlem Ünal; Turgay Coskun; James D Weisfeld-Adams; Nina L Schrager; Sabine Scholl-Bürgi; Andrea Schlune; Markus G Donner; Martin Hersberger; Claudio Gemperle; Brunhilde Riesner; Hanno Ulmer; Johannes Häberle; Daniela Karall
Journal:  J Inherit Metab Dis       Date:  2016-04-01       Impact factor: 4.982

8.  Lipid nanoparticle-targeted mRNA therapy as a treatment for the inherited metabolic liver disorder arginase deficiency.

Authors:  Brian Truong; Gabriella Allegri; Xiao-Bo Liu; Kristine E Burke; Xuling Zhu; Stephen D Cederbaum; Johannes Häberle; Paolo G V Martini; Gerald S Lipshutz
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-09       Impact factor: 11.205

9.  Myocyte-mediated arginase expression controls hyperargininemia but not hyperammonemia in arginase-deficient mice.

Authors:  Chuhong Hu; Jennifer Kasten; Hana Park; Ragini Bhargava; Denise S Tai; Wayne W Grody; Quynh G Nguyen; Stephen D Hauschka; Stephen D Cederbaum; Gerald S Lipshutz
Journal:  Mol Ther       Date:  2014-06-03       Impact factor: 11.454

10.  Human recombinant arginase enzyme reduces plasma arginine in mouse models of arginase deficiency.

Authors:  Lindsay C Burrage; Qin Sun; Sarah H Elsea; Ming-Ming Jiang; Sandesh C S Nagamani; Arthur E Frankel; Everett Stone; Susan E Alters; Dale E Johnson; Scott W Rowlinson; George Georgiou; Brendan H Lee
Journal:  Hum Mol Genet       Date:  2015-09-10       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.